Tuesday, 29 October 2013
Venue: Changing Age Opportunity Room, Newcastle Biomedical Research Building (NBRB), Institute for Ageing and Health, Campus for Ageing and Vitality
Speaker: Prof Francesco Falciani, University of Liverpool
Title: A Network Biology Approach Reveals Novel Regulators of Energy Metabolism in Ageing Skeletal Muscles.
Falciani is Professor in integrative Systems Biology at the University of Liverpool and holds an honorary Chair in Systems Biology at the University of Birmingham. He is the Director of the new Centre of Computational Biology and Modelling (CCBM) at Liverpool University, which has a focus in large-scale data integration across different disciplines. He leads an interdisciplinary group in Systems Biology with nine researchers with backgrounds ranging from physics, computer science and experimental biology. His current research strategy, which integrates both experimental and computational biology, has two main streams. The first is the development of novel computational methods to address the most important challenges in the emerging discipline of systems biology. These include network biology, reverse engineering and network modularization methods. The second is the application of these methods to understand complex biological systems, such as muscle degeneration in chronic inflammatory diseases.
Francesco is also a member of the Centre for Integrated research into Musculoskeletal Ageing (CIMA), a collaboration between the universities of Liverpool, Newcastle and Sheffield.
If you would like to speak to Francesco after the seminar, please contact Carole (firstname.lastname@example.org).
Monday, 21 October 2013
|Dr Louise Reynard outlines risk factors in osteoarthritis.|
Wednesday, 9 October 2013
Monday, 7 October 2013
Wednesday 16th October 2013
11:15 11:45 Ian Clark
(University of East Anglia)
(Cubby) Broccoli - ‘The Golden Gun’ for osteoarthritis?
11:45 12:00 David Wilkinson Serine proteinases in Osteoarthritis
12:00 12:15 Matt Barter microRNAs in chondrogenesis and osteoarthritis
12:15 12:45 TBC
12:45 14:00 LUNCH
14:00 14:30 Ray Boot-Handford
(University of Manchester)
Do increases in ER stress and loss of circadian rhythm contribute to the development of osteoarthritis?
14:30 14:45 Kasia Pirog
Mouse models of rare skeletal diseases as a tool to elucidate the pathomolecular mechanisms of osteoarthritis
14:45 15:00 Louise Reynard
Functional analysis of the osteoarthritis susceptibility locus residing at the carbohydrate sulfotransferase 11 gene CHST11
15:00 15:30 Chris Murphy
(University of Oxford) MicroRNA mediated regulation of chondrocyte function
15:30 16:00 coffee
16:00 16:15 Michael Ruston
Characterisation of the DNA methylome in knee and hip osteoarthritis
16:15 16:30 Rodolfo Gomez
Epigenetic control of MSC differentiation: Focus on adipocytic and osteoblastic fates
16:30 16:45 Mark Birch
Engineering biomaterials to influence musculoskeletal cell activity
16:45 17:15 Peter van der Kraan
(Radboud University Nijmegen Medical Centre, Netherlands) Role of TGF beta superfamily members in OA pathology
Thursday, 3 October 2013
Professor John Isaacs and his team have been awarded funding of £225,000 over three years to set up the Arthritis Research UK Experimental Arthritis Treatment Centre. They will test drugs for rheumatoid arthritis that are being studied for other conditions such as cancer, in small numbers of patients.
Rheumatoid arthritis affects nearly half a million people in the UK. It is a chronic, disabling condition in which the body's immune system attacks the joints. Although newer biologic treatments have made a huge difference to patients' lives, a proportion do not respond.
"We hope we can bring more treatment choices, in particular to test cancer drugs in patients with rheumatoid arthritis who have run out of options after trying all of the biologic drugs," explained Professor Isaacs, professor of clinical rheumatology at Institute of Cellular Medicine.
"At the other extreme, if we can find a treatment that 'switches off' arthritis, this could mean that patients with early disease only require a short-term treatment, after which they will not need to take drugs."
Being part of a trial
Professor Isaacs added that experimental medicine research could seem quite daunting to patients, as the treatments being tested were new and might not work, and the trials often involve a number of blood tests and other investigations.
"When patients become involved with research they generally benefit, regardless of the actual drug being tested. Because of this we feel it's very important for everyone to understand about research. Therefore we're also developing a programme of activities to provide better information to patients and their relatives, to help them to understand about research, and whether or not to become involved," he added.
The Newcastle researchers are working with pharmaceutical companies. "Often drug companies studying one disease can't afford to simultaneously test their drug in another condition such as arthritis, so we hope they will allow us to test their drugs for the, on our diseases," said Professor Isaacs. "If successful this will benefit the patient, the researchers, the company, the charity – and the economy – a win-win situation."
The new centre has already gained funding from the Medical Research Council to 're-purpose' a cancer drug called seliciclib being developed by Cyclacel Pharmaceuticals, a University of Dundee spin-out company.
Seliciclib has been evaluated to date in approximately 380 cancer patients and is currently being tested in combination with another Cyclacel drug in cancer patients with solid tumours.
Researchers hope to show that the treatment is safe and potentially effective. Initially they will treat patients who have had the condition for at least a year and who are already taking treatment but not responding well enough. If this research is successful then they will test the treatment in patients taking different treatments, at different stages of their illness.
Medical director of Arthritis Research UK Professor Alan Silman said: "There's a real need to do in-depth testing of the benefits and safety of new drugs in small numbers of patients before large scale trials can begin, and our new experimental arthritis treatment centres are providing the resources to study patients in these key first stage studies."
Tuesday, 1 October 2013
Another exicitng immunology talk is happening this week! "Modulation of immunity to pathogens by mast cells" will be presented by Prof. Soman Abraham of Duke University, USA. If you wish attend we'll be in LTF Newcastle University, 1pm this Thrusday. It would be a delight to see you there!